Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 12Recurrence 2Stomach Neoplasms 1Sarcoma, Synovial 1Plasmacytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 2Trastuzumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Azacitidine 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1saracatinib 1sapanisertib 1relatlimab 1pertuzumab 1pemigatinib 1palbociclib 1osimertinib 1orantinib 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cediranib 1cc-486 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Immunotherapy, Adoptive × Plasma cell × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡